-
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
-
Agile Therapeutics to Present at Upcoming Investor Conferences
-
Agile Therapeutics to Present at Upcoming Investor Conferences
-
No News to Explain Agile Therapeutics' (AGRX) Wild Move - Janney
-
Janney Montgomery Scott Downgrades Agile Therapeutics (AGRX) to Neutral (Friday)
-
Agile Therapeutics (AGRX): Study Shows Twirla Just As Effective As FDA-Approved Contraceptives - Janney
-
Agile Therapeutics (AGRX): Cutting PT To Account For Offering - Janney Montgomery Scott
-
Agile Therapeutics (AGRX) Prices 5.33M Common Stock Offering at $3.75/Share
-
Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
-
Agile Therapeutics (AGRX): Expect Acceptance Of NDA Next Week - Janney
-
Agile Therapeutics (AGRX): Phase 3 Pearl Index High but Explainable - Janney
-
Agile Therapeutics, Inc. Announces Full Exercise of Option to Purchase Additional Shares by Underwriters
-
Agile Therapeutics (AGRX) Prices 5.5M Common Stock Offering at $6.35/Share
-
Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
-
Agile Therapeutics (AGRX) Plans $30M Common Stock Offering
-
Agile Therapeutics Announces Proposed Offering of Common Stock
-
Janney Starts Agile Therapeutics (AGRX) at Buy
-
Agile Therapeutics (AGRX) IPO Opens 8% Lower
-
Agile Therapeutics (AGRX) Prices IPO at $6

